Company intelligence / Profile preview

OncoVista Innovative Therapies

San Antonio, Texas, United Statesoncovista.com ↗

Ownership: Private
Employees: ~2
Development stage: Other

Overview

OncoVista Innovative Therapies was a clinical-stage biopharmaceutical company focused on targeted anti-cancer therapies, particularly small molecule programs. Its lead programs, cordycepin (OVI-123) and L-nucleoside conjugate (OVI-117), reached Phase 1/2 and preclinical/IND stages respectively for various leukemias and solid tumors. The company became dormant in 2016, with product rights reverting to licensors and no evidence of active development or clinical enrollment since.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

cordycepin

1 more asset in the full pipeline.

Partnerships

Lipitek International (licensor of OVI-117, rights reverted as of 2016)[9]

Beyond the preview

Go deeper on OncoVista Innovative Therapies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OncoVista Innovative Therapies.